Dupilumab reduced asthma exacerbations by ~90% in RCT
www.pulmccm.org
Dupilumab, an injectable monoclonal antibody that inhibits signaling by interleukin-4 and interleukin-13, reduced asthma exacerbations by almost 90% while also improving asthma symptoms in a randomized trial. Participants had moderate-to-severe asthma that had previously been uncontrolled despite use of inhaled corticosteroids with long-acting beta-agonists.
Dupilumab reduced asthma exacerbations by ~90% in RCT
Dupilumab reduced asthma exacerbations by…
Dupilumab reduced asthma exacerbations by ~90% in RCT
Dupilumab, an injectable monoclonal antibody that inhibits signaling by interleukin-4 and interleukin-13, reduced asthma exacerbations by almost 90% while also improving asthma symptoms in a randomized trial. Participants had moderate-to-severe asthma that had previously been uncontrolled despite use of inhaled corticosteroids with long-acting beta-agonists.